Last reviewed · How we verify
Lantus
Lantus, marketed by Rijnstate Hospital, is a leading treatment for type 1 diabetes mellitus. Its key strength lies in its well-established market presence, supported by a key composition patent that remains in effect until 2028. The primary risk to Lantus is the eventual patent expiry in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | Lantus |
|---|---|
| Also known as | Insulin Glargine, Metformin, gliclazide modified release tablets, acarbose, insulin glargine |
| Sponsor | Rijnstate Hospital |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Diabetes mellitus type 1
- Diabetes mellitus type 2
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
- Pruritus
- Rash
- Edema
- Allergic reactions
- Peripheral edema
- Lipoatrophy
- Lipohypertrophy
Serious adverse events
- Severe symptomatic hypoglycemia
- Worsening of diabetic retinopathy
- Acute painful peripheral neuropathy
- Ophthalmologic refraction disorder
Key clinical trials
- Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes (NA)
- Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes (PHASE2)
- iGlarLixi CGM Study in Chinese T2D Individuals After OADs (PHASE4)
- Effect of Topical Insulin on Healing Rate of Pemphigus Lesions (PHASE2)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes (PHASE3)
- Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes (PHASE4)
- A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lantus CI brief — competitive landscape report
- Lantus updates RSS · CI watch RSS
- Rijnstate Hospital portfolio CI